# BMX

## Overview
BMX is a gene that encodes the BMX non-receptor tyrosine kinase, a member of the Tec family of kinases. This protein is characterized by its role in various cellular processes, including signal transduction, cell proliferation, differentiation, and survival. Unlike receptor tyrosine kinases, BMX functions independently of ligand binding to a receptor, instead being activated by intracellular signaling pathways. The BMX protein is particularly significant in the regulation of inflammatory responses and is expressed in hematopoietic cells, such as granulocytes and monocytes, as well as in epithelial cells where it influences barrier function. BMX's kinase activity is crucial for its involvement in these processes, making it a potential target for therapeutic interventions in diseases such as cancer and inflammatory conditions (Cenni2012BMX; HammAlvarez2001EtkBmx; Palmer2008Bmx).

## Structure
BMX, a member of the Tec family of non-receptor tyrosine kinases, is characterized by a conserved domain structure that includes a pleckstrin homology (PH) domain at the N-terminus, followed by Src homology 3 (SH3) and Src homology 2 (SH2) domains, and a kinase domain (Chen2013Tyrosine; Wu2001Proteolytic). The PH domain is crucial for membrane targeting in response to phosphatidylinositol-3 kinase (PI3K) activation, and it can also interact with the FERM domain of focal adhesion kinase (FAK) (Chen2013Tyrosine). BMX lacks a C-terminal tyrosine that negatively regulates Src kinases and a proline-rich motif between the SH3 and SH2 domains, distinguishing it from other Tec kinases (Chen2013Tyrosine).

The primary structure of BMX includes a unique 'SH3-like' domain with a truncated form of SH3 surrounded by duplicated stretches (Smith2001The). BMX is subject to post-translational modifications such as phosphorylation, which modulate its activity (Wu2001Proteolytic). BMX may also have splice variant isoforms, which can influence its function and localization (Seixas2020Structural). The tertiary and quaternary structures of BMX have not been detailed in the available context.

## Function
BMX (BMX non-receptor tyrosine kinase) is a member of the Tec family of tyrosine kinases and plays a significant role in various cellular processes, including signal transduction, cell proliferation, differentiation, and survival. In healthy human cells, BMX is involved in the regulation of inflammatory cytokine production, particularly in macrophages. It regulates TLR4-induced IL-6 production independently of p38 MAPK and NF-κB activity, highlighting its unique role in immune response modulation (Palmer2008Bmx).

BMX is expressed in hematopoietic cells of the myeloid lineage, such as granulocytes and monocytes, and is involved in the response to ischemia and pressure overload in cardiac endothelium. It plays a role in the secretion of proinflammatory cytokines induced by TNFα, IL-1β, and TLR agonists, acting at the level of the TAK1/TAB complex (Cenni2012BMX). BMX is also implicated in the stabilization of IL-6 mRNA in macrophages, contributing to its role in inflammation (Cenni2012BMX).

In epithelial cells, BMX modulates barrier function by enhancing transepithelial resistance and influencing the organization of adherens junctions, which is crucial for maintaining epithelial integrity (HammAlvarez2001EtkBmx). BMX's kinase activity is essential for its function, making it a potential target for therapeutic interventions in inflammation and cancer (Cenni2012BMX).

## Clinical Significance
Alterations in the expression and activity of the BMX gene have been implicated in several diseases, particularly in cancer and inflammatory conditions. In prostate cancer, BMX is upregulated in castration-resistant prostate cancer (CRPC) and abiraterone-resistant prostate cancer. This upregulation is associated with resistance to androgen deprivation therapy (ADT), suggesting that BMX contributes to the progression and treatment resistance of prostate cancer (Chen2018BMXMediated). BMX is also involved in acute myeloid leukemia (AML), where its expression is increased under hypoxic conditions, contributing to resistance against the drug sorafenib. This resistance is not due to mutations but is linked to the hypoxic tumor microenvironment, highlighting BMX's role in therapeutic resistance (van2017Hypoxiainduced).

In inflammatory diseases, BMX is implicated in rheumatoid arthritis (RA), where it is activated in synovial fibroblasts and is necessary for cytokine secretion. BMX deficiency in mice has shown protection from arthritis in certain models, indicating its role in inflammatory signaling pathways (Cenni2012BMX). BMX's involvement in these diseases suggests its potential as a therapeutic target and biomarker in various pathological conditions.

## Interactions
BMX, a non-receptor tyrosine kinase, participates in various protein interactions that are crucial for its role in cellular signaling pathways. In prostate cancer cells, BMX is activated downstream of phosphoinositide 3-kinase (PI3K) and Src, particularly in PTEN-deficient cells. It interacts with ErbB3, a major tyrosine-phosphorylated protein, suggesting that ErbB2, which mediates ErbB3 phosphorylation, may act as an upstream activator of BMX (Jiang2007Activation). BMX also interacts with epidermal growth factor receptor (EGFR) and ErbB3 in a ligand-dependent manner, with its activation involving complex signaling pathways including PI3K and Src (Jiang2007Activation).

BMX forms a complex with Rap1, a small GTPase, upon VEGF stimulation, indicating its role in VEGF-induced endothelial cell activation. This interaction is crucial for cell migration processes, as inhibiting BMX blocks VEGF-induced cell migration (Stoletov2004Bmx). BMX is also involved in the TNF-induced angiogenic pathway, where it transactivates VEGFR2 and recruits PI3K to mediate signaling (Zhang2003Etk/Bmx). These interactions highlight BMX's involvement in various signaling pathways that regulate cell growth, survival, and differentiation.


## References


[1. (Cenni2012BMX) Bruno Cenni, Sascha Gutmann, and Marie Gottar-Guillier. Bmx and its role in inflammation, cardiovascular disease, and cancer. International Reviews of Immunology, 31(2):166–173, March 2012. URL: http://dx.doi.org/10.3109/08830185.2012.663838, doi:10.3109/08830185.2012.663838. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/08830185.2012.663838)

[2. (Zhang2003Etk/Bmx) Rong Zhang, Yingqian Xu, Niklas Ekman, Zhenhua Wu, Jiong Wu, Kari Alitalo, and Wang Min. Etk/bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. Journal of Biological Chemistry, 278(51):51267–51276, December 2003. URL: http://dx.doi.org/10.1074/jbc.m310678200, doi:10.1074/jbc.m310678200. This article has 121 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m310678200)

[3. (HammAlvarez2001EtkBmx) Sarah F. Hamm-Alvarez, Allen Chang, Yanru Wang, Galina Jerdeva, H. Helen Lin, Kwang-Jin Kim, and David K. Ann. Etk/bmx activation modulates barrier function in epithelial cells. American Journal of Physiology-Cell Physiology, 280(6):C1657–C1668, June 2001. URL: http://dx.doi.org/10.1152/ajpcell.2001.280.6.C1657, doi:10.1152/ajpcell.2001.280.6.c1657. This article has 26 citations.](https://doi.org/10.1152/ajpcell.2001.280.6.C1657)

[4. (Jiang2007Activation) Xinnong Jiang, Robert A. Borgesi, Nicole C. McKnight, Ramneet Kaur, Christopher L. Carpenter, and Steven P. Balk. Activation of nonreceptor tyrosine kinase bmx/etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and erbb3 in prostate cancer cells. Journal of Biological Chemistry, 282(45):32689–32698, November 2007. URL: http://dx.doi.org/10.1074/jbc.m703412200, doi:10.1074/jbc.m703412200. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m703412200)

[5. (van2017Hypoxiainduced) Jolieke G. van Oosterwijk, Daelynn R. Buelow, Christina D. Drenberg, Aksana Vasilyeva, Lie Li, Lei Shi, Yong-Dong Wang, David Finkelstein, Sheila A. Shurtleff, Laura J. Janke, Stanley Pounds, Jeffrey E. Rubnitz, Hiroto Inaba, Navjotsingh Pabla, and Sharyn D. Baker. Hypoxia-induced upregulation of bmx kinase mediates therapeutic resistance in acute myeloid leukemia. Journal of Clinical Investigation, 128(1):369–380, December 2017. URL: http://dx.doi.org/10.1172/jci91893, doi:10.1172/jci91893. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci91893)

[6. (Stoletov2004Bmx) Konstantin V Stoletov and Bruce I Terman. Bmx is a downstream rap1 effector in vegf-induced endothelial cell activation. Biochemical and Biophysical Research Communications, 320(1):70–75, July 2004. URL: http://dx.doi.org/10.1016/j.bbrc.2004.05.134, doi:10.1016/j.bbrc.2004.05.134. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2004.05.134)

[7. (Smith2001The) C.I. Edvard Smith, Tahmina C. Islam, Pekka T. Mattsson, Abdalla J. Mohamed, Beston F. Nore, and Mauno Vihinen. The tec family of cytoplasmic tyrosine kinases: mammalian btk, bmx, itk, tec, txk and homologs in other species. BioEssays, 23(5):436–446, April 2001. URL: http://dx.doi.org/10.1002/bies.1062, doi:10.1002/bies.1062. This article has 226 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bies.1062)

[8. (Palmer2008Bmx) Christine D. Palmer, Brenda E. Mutch, Sarita Workman, John P. McDaid, Nicole J. Horwood, and Brian M. J. Foxwell. Bmx tyrosine kinase regulates tlr4-induced il-6 production in human macrophages independently of p38 mapk and nfκb activity. Blood, 111(4):1781–1788, February 2008. URL: http://dx.doi.org/10.1182/blood-2007-07-102343, doi:10.1182/blood-2007-07-102343. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2007-07-102343)

[9. (Chen2013Tyrosine) Sen Chen, Xinnong Jiang, Christina A. Gewinner, John M. Asara, Nicholas I. Simon, Changmeng Cai, Lewis C. Cantley, and Steven P. Balk. Tyrosine kinase bmx phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Science Signaling, May 2013. URL: http://dx.doi.org/10.1126/scisignal.2003936, doi:10.1126/scisignal.2003936. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2003936)

[10. (Chen2018BMXMediated) Sen Chen, Changmeng Cai, Adam G. Sowalsky, Huihui Ye, Fen Ma, Xin Yuan, Nicholas I. Simon, Nathanael S. Gray, and Steven P. Balk. Bmx-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Research, 78(18):5203–5215, September 2018. URL: http://dx.doi.org/10.1158/0008-5472.CAN-17-3615, doi:10.1158/0008-5472.can-17-3615. This article has 25 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-17-3615)

[11. (Seixas2020Structural) João D. Seixas, Bárbara B. Sousa, Marta C. Marques, Ana Guerreiro, Rui Traquete, Tiago Rodrigues, Inês S. Albuquerque, Marcos F. Q. Sousa, Ana R. Lemos, Pedro M. F. Sousa, Tiago M. Bandeiras, Di Wu, Shelby K. Doyle, Carol V. Robinson, Angela N. Koehler, Francisco Corzana, Pedro M. Matias, and Gonçalo J. L. Bernardes. Structural and biophysical insights into the mode of covalent binding of rationally designed potent bmx inhibitors. RSC Chemical Biology, 1(4):251–262, 2020. URL: http://dx.doi.org/10.1039/d0cb00033g, doi:10.1039/d0cb00033g. This article has 7 citations.](https://doi.org/10.1039/d0cb00033g)

[12. (Wu2001Proteolytic) Yi-Mi Wu, Chia-Lin Huang, Hsing-Jien Kung, and Chi-Ying F. Huang. Proteolytic activation of etk/bmx tyrosine kinase by caspases. Journal of Biological Chemistry, 276(21):17672–17678, May 2001. URL: http://dx.doi.org/10.1074/jbc.M010964200, doi:10.1074/jbc.m010964200. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M010964200)